Table 2.
Number of detected biopeptide sequences (with identified bioactivity) generated from the tested protein preparations by the analyzed L. helveticus strains.
| Bioactivity | Source of peptides (type of analyzed hydrolysate) | Number of bioactive peptide sequences generated by the tested L. helveticus strains | |||
|---|---|---|---|---|---|
| B734 | DSMZ | T80 | T105 | ||
| Antihypertensive | CGMP | 24 | 17 | 18 | 24 |
| α-la | 7 | 7 | 7 | 9 | |
| ACE inhibitory | CGMP | 8 | 9 | 5 | 8 |
| α-la | 3 | 3 | 4 | 4 | |
| Antithrombotic | CGMP | 3 | 2 | 2 | 3 |
| α-la | — | — | — | — | |
| Antioxidative | CGMP | 3 | 2 | 3 | 4 |
| α-la | 1 | 1 | 1 | 1 | |
| Antimicrobial/antibacterial | CGMP | 4 | 3 | 4 | 3 |
| α-la | 3 | 2 | 2 | 2 | |
| Immunomodulating/immuno- and cytomodulatory peptides | CGMP | 2 | 3 | 2 | 3 |
| α-la | 2 | 2 | 2 | 2 | |
| Mineral binding | CGMP | — | 1 | 1 | — |
| α-la | — | — | — | — | |
| Opioid agonist | CGMP | — | 1 | — | — |
| α-la | — | — | — | — | |
| Total number of identified different biopeptide sequences | CGMP α-la |
29 11 |
24 11 |
26 8 |
29 12 |